In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Bone Marrow Transplantation, Published online: 31 January 2024; doi:10.1038/s41409-023-02160-8In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Source: Bone Marrow Transplantation - January 31, 2024 Category: Hematology Authors: Meral Beksac Diderik-Jan Eikema Linda Koster Cyrille Hulin Xavier Poir é Rose-Marie Hamladji Tomasz Gromek Ali Bazarbachi Zubeyde Nur Ozkurt Thomas Pabst Tarek Ben Othman J ürgen Finke Olga Pirogova Depei Wu Amjad Hayat Inken Hilgendorf Eleni Tholouli L Source Type: research